Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections

Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections

Objectives: This study was conducted to evaluate the clinical experience with daptomycin in the treatment of resistant gram-positive infections (GPIs) in patients with HIV infection. Methods: Using a retrospective, multicenter, and observational registry study, investigators assessed outcomes follow...

Full description

Bibliographic Details
Main Authors: Jihad Slim MD, Humberto Jimenez PharmD, Darren Culshaw PharmD, Hina Patel PharmD, Kenneth C. Lamp PharmD
Format: Article
Language:English
Published: SAGE Publishing 2015-05-01
Series:Journal of the International Association of Providers of AIDS Care
Online Access:https://doi.org/10.1177/2325957414553840
id doaj-5fceada6486d4e998ef0ba07a06af2e3
record_format Article
spelling doaj-5fceada6486d4e998ef0ba07a06af2e32020-11-25T03:09:34ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95742325-95822015-05-011410.1177/2325957414553840Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive InfectionsJihad Slim MD0Humberto Jimenez PharmD1Darren Culshaw PharmD2Hina Patel PharmD3Kenneth C. Lamp PharmD4 Saint Michael’s Medical Center, Infectious Diseases Department Newark, NJ, USA JFK Medical Center, Comprehensive Pharmacy Services Edison, NJ, USA Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USA Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USA Medical Affairs, Cubist Pharmaceuticals, Lexington, MA, USAObjectives: This study was conducted to evaluate the clinical experience with daptomycin in the treatment of resistant gram-positive infections (GPIs) in patients with HIV infection. Methods: Using a retrospective, multicenter, and observational registry study, investigators assessed outcomes following daptomycin therapy in 78 patients (62 efficacy evaluable) infected with HIV and with resistant GPIs. Results: Overall, success rates by infection type were bacteremia 91% (20 of 22), endocarditis 91% (10 of 11), and bone/joint 100% (9 of 9). Success by pathogen was 93% (39 of 42), 93% (14 of 15), and 100% (5 of 5) for methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, and methicillin-resistant coagulase-negative staphylococci, respectively. Daptomycin appeared to be well tolerated, with 9% having an adverse event possibly related to daptomycin and 4% discontinuing daptomycin. Conclusions: In HIV-infected patients, daptomycin appears to be a useful agent for treating resistant GPIs.https://doi.org/10.1177/2325957414553840
collection DOAJ
language English
format Article
sources DOAJ
author Jihad Slim MD
Humberto Jimenez PharmD
Darren Culshaw PharmD
Hina Patel PharmD
Kenneth C. Lamp PharmD
spellingShingle Jihad Slim MD
Humberto Jimenez PharmD
Darren Culshaw PharmD
Hina Patel PharmD
Kenneth C. Lamp PharmD
Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
Journal of the International Association of Providers of AIDS Care
author_facet Jihad Slim MD
Humberto Jimenez PharmD
Darren Culshaw PharmD
Hina Patel PharmD
Kenneth C. Lamp PharmD
author_sort Jihad Slim MD
title Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
title_short Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
title_full Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
title_fullStr Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
title_full_unstemmed Daptomycin Experience in Patients with Human Immunodeficiency Virus and Resistant Gram-Positive Infections
title_sort daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections
publisher SAGE Publishing
series Journal of the International Association of Providers of AIDS Care
issn 2325-9574
2325-9582
publishDate 2015-05-01
description Objectives: This study was conducted to evaluate the clinical experience with daptomycin in the treatment of resistant gram-positive infections (GPIs) in patients with HIV infection. Methods: Using a retrospective, multicenter, and observational registry study, investigators assessed outcomes following daptomycin therapy in 78 patients (62 efficacy evaluable) infected with HIV and with resistant GPIs. Results: Overall, success rates by infection type were bacteremia 91% (20 of 22), endocarditis 91% (10 of 11), and bone/joint 100% (9 of 9). Success by pathogen was 93% (39 of 42), 93% (14 of 15), and 100% (5 of 5) for methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, and methicillin-resistant coagulase-negative staphylococci, respectively. Daptomycin appeared to be well tolerated, with 9% having an adverse event possibly related to daptomycin and 4% discontinuing daptomycin. Conclusions: In HIV-infected patients, daptomycin appears to be a useful agent for treating resistant GPIs.
url https://doi.org/10.1177/2325957414553840
work_keys_str_mv AT jihadslimmd daptomycinexperienceinpatientswithhumanimmunodeficiencyvirusandresistantgrampositiveinfections
AT humbertojimenezpharmd daptomycinexperienceinpatientswithhumanimmunodeficiencyvirusandresistantgrampositiveinfections
AT darrenculshawpharmd daptomycinexperienceinpatientswithhumanimmunodeficiencyvirusandresistantgrampositiveinfections
AT hinapatelpharmd daptomycinexperienceinpatientswithhumanimmunodeficiencyvirusandresistantgrampositiveinfections
AT kennethclamppharmd daptomycinexperienceinpatientswithhumanimmunodeficiencyvirusandresistantgrampositiveinfections
_version_ 1724661895313489920

Similar Items